Emzor Raises N26.7bn Bond to Drive Local Drug Production, Complete Anti-Malarial API Plant

Olufemi Adeyemi Five-year bond oversubscribed as pharmaceutical firm deepens investment in critical drug ingredients Emzor Pharmaceutical Industries has secured N26.7 billion ($19.8 million) through a Series 1 Fixed Rate Bond on the FMDQ Group Exchange, in a major financing move aimed at expanding domestic pharmaceutical production and completing what the company describes as West Africa’s first full-scale anti-malarial Active Pharmaceutical Ingredient (API) manufacturing facility. The five-year bond, issued at a 19 per cent coupon through Emzor’s special purpose vehicle, Emzor Pharma Funding SPV Plc, was oversubscribed following strong demand from investors. The fundraising forms part of Emzor’s wider N40 billion ($29.6 million) bond issuance programme and represents the company’s second domestic bond transaction. Proceeds from the latest issue are expected to provide working capital, increase manufacturing capacity and accelerate the completion of the company’s anti-malarial API facility. The transaction comes at a time when Nigeria’s pharmaceutical industry continues to grapple with heavy reliance on imported medicines and raw materials, exposing manufacturers to foreign exchange pressures, international supply-chain disruptions and fluctuations in global commodity and shipping costs. With the new investment, Emzor is seeking to move further up the pharmaceutical value chain by manufacturing critical ingredients locally rather than depending predominantly on imported inputs. From medicine manufacturing to API production The planned anti-malarial API facility represents one of the most significant components of Emzor’s current investment programme. Active Pharmaceutical Ingredients are the substances in medicines responsible for producing their therapeutic effects. Although pharmaceutical manufacturing has expanded across parts of Africa, the production of APIs remains highly concentrated outside the continent. This dependence means African drug manufacturers can face difficulties when international supply chains are disrupted or when shortages of foreign exchange make imported pharmaceutical ingredients more expensive or difficult to obtain. For Nigerian manufacturers, local API production could help address some of these challenges by creating a more reliable source of essential pharmaceutical inputs. It could also reduce exposure to currency volatility and import-related costs while supporting greater domestic value addition in the pharmaceutical sector. Emzor’s investment therefore has implications beyond the company’s own production capacity. The development of local API manufacturing could contribute to the emergence of a stronger pharmaceutical supply chain in Nigeria, with potential benefits for medicine availability and supply security. A company with roots in Lagos Emzor’s expansion marks a significant evolution for a company that began in 1977 as a small chemist shop in Lagos. Founded by pharmacist Stella Okoli, the business has grown into one of Nigeria’s leading pharmaceutical manufacturers, producing more than 120 medicines across 16 therapeutic categories. The company’s latest capital-raising exercise reflects its ambition to build on that manufacturing base by producing some of the critical pharmaceutical ingredients traditionally sourced from overseas. The successful bond issue also demonstrates investor appetite for financing opportunities within Nigeria’s healthcare and manufacturing sectors, particularly businesses seeking to expand domestic production. Reducing import dependence Nigeria remains substantially dependent on imported pharmaceutical ingredients and finished medicines. That dependence can place pressure on manufacturers whenever foreign exchange becomes scarce or the naira weakens against major international currencies. Import dependence can also expose the local industry to global disruptions beyond the control of domestic manufacturers, including changes in international prices, shipping constraints and interruptions in production abroad. Increasing domestic production of APIs could help insulate manufacturers from some of these external shocks. For Emzor, the completion of the anti-malarial API plant could consequently represent more than an expansion of its product portfolio. It could establish a new manufacturing capability focused on supplying one of the most important components of pharmaceutical production. The move also aligns with broader efforts to strengthen Nigeria’s industrial base, encourage local manufacturing and reduce dependence on imported healthcare products. Financing a deeper pharmaceutical value chain The N26.7 billion bond gives Emzor additional financial capacity to pursue these objectives while maintaining the working capital required for its existing operations. Its inclusion in the company’s N40 billion bond programme provides room for further financing as Emzor advances its broader expansion plans. The oversubscription of the issue suggests that demand for the company’s debt was stronger than the amount initially available, giving the transaction an additional vote of confidence from the investment community. As Emzor progresses from being primarily a manufacturer of finished medicines towards producing critical pharmaceutical inputs, its latest fundraising could become an important milestone in the development of Nigeria’s pharmaceutical manufacturing ecosystem. The completion of the anti-malarial API facility, in particular, would represent a significant step towards greater local value addition and could help reduce some of the vulnerabilities associated with Nigeria’s dependence on imported pharmaceutical raw materials. Ultimately, Emzor’s latest financing underscores a growing push within the Nigerian pharmaceutical industry to build production capacity locally, strengthen supply chains and develop the infrastructure required to manufacture more of the medicines—and the ingredients that go into them—within the country.